BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 17117522)

  • 1. Decitabine.
    Gore SD; Jones C; Kirkpatrick P
    Nat Rev Drug Discov; 2006 Nov; 5(11):891-2. PubMed ID: 17117522
    [No Abstract]   [Full Text] [Related]  

  • 2. [Hypomethylating agents for the treatment of myelodysplastic syndromes].
    Itzykson R; Fenaux P
    Bull Cancer; 2011 Aug; 98(8):927-34. PubMed ID: 21821482
    [TBL] [Abstract][Full Text] [Related]  

  • 3. DNA methylation inhibitors in the treatment of leukemias, myelodysplastic syndromes and hemoglobinopathies: clinical results and possible mechanisms of action.
    Lübbert M
    Curr Top Microbiol Immunol; 2000; 249():135-64. PubMed ID: 10802943
    [No Abstract]   [Full Text] [Related]  

  • 4. Approval summary: azacitidine for treatment of myelodysplastic syndrome subtypes.
    Kaminskas E; Farrell A; Abraham S; Baird A; Hsieh LS; Lee SL; Leighton JK; Patel H; Rahman A; Sridhara R; Wang YC; Pazdur R;
    Clin Cancer Res; 2005 May; 11(10):3604-8. PubMed ID: 15897554
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 5-Azacytidine for the treatment of myelodysplastic syndromes.
    Krawczyk J; Keane N; Freeman CL; Swords R; O'Dwyer M; Giles FJ
    Expert Opin Pharmacother; 2013 Jun; 14(9):1255-68. PubMed ID: 23621771
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FDA drug approval summary: azacitidine (5-azacytidine, Vidaza) for injectable suspension.
    Kaminskas E; Farrell AT; Wang YC; Sridhara R; Pazdur R
    Oncologist; 2005 Mar; 10(3):176-82. PubMed ID: 15793220
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Methylation inhibitor therapy in the treatment of myelodysplastic syndrome.
    Silverman LR; Mufti GJ
    Nat Clin Pract Oncol; 2005 Dec; 2 Suppl 1():S12-23. PubMed ID: 16341236
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Is there an association between 5-azacitidine and ototoxicity?
    Malik A; Misbah S; Spaccavento C; Yudelman I
    J Clin Pharmacol; 2010 Sep; 50(9):1056-7. PubMed ID: 20234015
    [No Abstract]   [Full Text] [Related]  

  • 9. Decitabine in myelodysplastic syndromes: viewpoints.
    Garcia-Manero G; Saba HI
    Drugs; 2006; 66(7):959-60. PubMed ID: 16740015
    [No Abstract]   [Full Text] [Related]  

  • 10. [Demethylating medication in myelodysplastic syndrome].
    Manson ML; Derissen EJ; Wijermans PW; Schellens JH; Beijnen JH
    Ned Tijdschr Geneeskd; 2012; 156(4):A3167. PubMed ID: 22278034
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Azacitidine.
    Issa JP; Kantarjian HM; Kirkpatrick P
    Nat Rev Drug Discov; 2005 Apr; 4(4):275-6. PubMed ID: 15861567
    [No Abstract]   [Full Text] [Related]  

  • 12. Decitabine in the treatment of myelodysplastic syndromes.
    Santos FP; Kantarjian H; Garcia-Manero G; Issa JP; Ravandi F
    Expert Rev Anticancer Ther; 2010 Jan; 10(1):9-22. PubMed ID: 20014881
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Will next-generation agents deliver on the promise of epigenetic hypomethylation therapy?
    Lowder JN; Taverna P; Issa JP
    Epigenomics; 2015 Oct; 7(7):1083-8. PubMed ID: 26541345
    [No Abstract]   [Full Text] [Related]  

  • 14. Histiocytoid Sweet's syndrome potentially related to decitabine in a patient with myelodysplastic syndrome.
    Park JY; Park JS; Kim YC
    Eur J Dermatol; 2012; 22(6):811-2. PubMed ID: 23178879
    [No Abstract]   [Full Text] [Related]  

  • 15. Epigenetic therapy with decitabine for myelodysplasia and leukemia.
    Wijermans P; Lübert M
    Future Oncol; 2005 Oct; 1(5):585-91. PubMed ID: 16556035
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical results with the DNA hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in patients with myelodysplastic syndromes: an update.
    Joeckel TE; Lübbert M
    Semin Hematol; 2012 Oct; 49(4):330-41. PubMed ID: 23079063
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Decitabine versus 5-azacitidine for the treatment of myelodysplastic syndrome: adjusted indirect meta-analysis.
    Kumar A; List AF; Hozo I; Komrokji R; Djulbegovic B
    Haematologica; 2010 Feb; 95(2):340-2; author reply 343-4. PubMed ID: 19850902
    [No Abstract]   [Full Text] [Related]  

  • 18. 5-azacytidine and decitabine monotherapies of myelodysplastic disorders.
    Kuykendall JR
    Ann Pharmacother; 2005 Oct; 39(10):1700-9. PubMed ID: 16144884
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Decreased incidence of febrile episodes with antibiotic prophylaxis in the treatment of decitabine for myelodysplastic syndrome.
    Lee JH; Lee KH; Lee JH; Kim DY; Kim SH; Lim SN; Kim SD; Choi Y; Lee SM; Lee WS; Choi MY; Joo YD
    Leuk Res; 2011 Apr; 35(4):499-503. PubMed ID: 20674021
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The clinical research of treatment by decitabine moderate or high-risk myelodysplastic syndrome patients].
    Shao XR; Liang H; Guan XJ
    Zhonghua Xue Ye Xue Za Zhi; 2011 Nov; 32(11):789-91. PubMed ID: 22339920
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.